“Blood sample” .. an Egyptian scientist makes a huge discovery that traps cancer


And the scientist Cyril Shahdi concluded that cancer tumors secrete a liquid genetic material in the patient’s blood, and through this material and its analysis, millions of information about the developments of the disease can be obtained.

Through this also, it is possible to develop treatment plans for a cancerous tumor and determine the extent of its response to treatment or not, as well as relief from the misery of surgical procedures for taking solid samples from tumors and replacing that with the liquid sample discovered by the Egyptian scientist.

Shahdi, Assistant Lecturer, University College of Medicine CairoHe made this discovery by leading a large research team in the United States. This team included researchers from Weill Cornell Medical College in New York, Cairo University, the Cancer Institute of Nevada and University of Washington and Harvard University.

The famous scientific journal Nature, through its oldest journal, the English Cancer Journal, celebrated this achievement and dedicated a special issue to it detailing its details on January 19.

According to the study published in “Nature”, Cyril and his research team noticed that part of the genetic material of malignant tumors finds its way from the tumor to the blood vessels in the form of a liquid substance, and it has become easy to perform genetic analyzes on the genetic material liquid in blood to help better understand the changes The genetic material that occurs during disease progression without exposing the patient to repeated sampling of the tumor Which requires complex surgical procedures that are not suitable for most patients.

The research team, which also includes among its members the Egyptian Bishoy Felts, conducted an extensive study to answer an important question for patients with bladder cancer, which is whether it is possible to use liquid genetic material to predict tumor response to treatment and understand the causes of disease resistance to treatment?

Cyril Shahdi told “Sky News Arabia” that his research team, to answer this question, analyzed 182 liquid samples collected from 53 patients with advanced stages of bladder cancer while receiving treatment over a period of five years, and the liquid genetic material in those samples was analyzed using Advanced technology, which enables us to know the genetic mutations and their quantity in the sample.

He added, “This study is one of the largest clinical studies on the follow-up of the fluid genetic material in blood in patients with leukemia Cancer bladder”.

He continued, “The doctor always stands unable to tell the patient, who is in an advanced stage, whether there is a real benefit from treatment or not. Today, we give the doctor and patient new hope and provide an important guideline for a better treatment plan.”

The study proves that the quantification of liquid genetic material is a true expression of tumor size and severity, and that patients whose blood contains high amounts of tumor genetic material are prone to more aggressive progression and a lower rate of survival than their counterparts with low amounts.

According to Shahdi, the study proves that “the genetic analysis of the liquid genetic material in the blood predicts which patients will respond in an extended manner to treatment, and that the genetic analysis can predict the development of the disease over time.” treatment“.

The study showed that the quantitative change of the liquid genetic material can predict treatment failure about three months before it appears using conventional CT scans, which gives the doctor ample time to change the treatment plan, according to Kirls Shahdi.

He stressed: “There is no doubt that this study will open the door to many therapeutic applications that depend on understanding the structure of tumor Individually and personally, each patient is treated with a separate plan based on the characteristics of his tumor.”

It should be noted that Dr. Cyril Shahdi, who achieved this huge achievement, was born in a village in the governorate Sohag In Upper Egypt, he graduated from the Faculty of Medicine of Cairo University, completed his training in oncology at Cairo University, and received a fellowship from the American Society of Oncology to complete his research on bladder cancer at Weill Cornell Medical College in New York. Most recently, Shahdi joined the Center for Experimental Oncology at Christie’s Institute, UK, to lead the Advanced Immunotherapy Program.

Shahdi had previously achieved a great achievement at the end of 2020, when he reached the genetic makeup of cancer. The young Egyptian confirms that he is continuing his research to find the best ways to eliminate this disease that threatens humanity, and most homes suffer from it, especially in Egypt.

Source link


Please enter your comment!
Please enter your name here